BIOA BioAge Labs Inc.

Price (delayed)

$7.89

Market cap

$362.13M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.38

Enterprise value

$291M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 30

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. BioAge’s lead product candidate, azelaprag, is an orally available small ...

Highlights
The revenue has soared by 168% YoY
The gross profit has surged by 168% year-on-year
BIOA's quick ratio is down by 31% since the previous quarter but it is up by 27% year-on-year
BIOA's EPS has dropped by 132% year-on-year
BIOA's net income is down by 20% year-on-year and by 5% since the previous quarter

Key stats

What are the main financial stats of BIOA

BIOA stock price

How has the BioAge Labs stock price performed over time
Intraday
-6.74%
1 week
1.81%
1 month
-16.77%
1 year
59.72%
YTD
-40.36%
QTD
-67.81%

Financial performance

How have BioAge Labs's revenue and profit performed over time
Revenue
$10.36M
Gross profit
$10.36M
Operating income
-$106.27M
Net income
-$94.46M
Gross margin
100%
Net margin
-912.3%
The revenue has soared by 168% YoY
The gross profit has surged by 168% year-on-year
The operating margin has soared by 57% YoY but it has contracted by 4.1% from the previous quarter
BIOA's net margin has surged by 55% year-on-year but it is down by 4.6% since the previous quarter

Price vs fundamentals

How does BIOA's price correlate with its fundamentals

Growth

What is BioAge Labs's growth rate over time

Valuation

What is BioAge Labs stock price valuation
P/E
N/A
P/B
0.94
P/S
34.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
28.1
BIOA's EPS has dropped by 132% year-on-year
The P/B is 47% less than the last 4 quarters average of 1.9
The company's equity rose by 27% YoY
The revenue has soared by 168% YoY
The stock's price to sales (P/S) is 45% less than its last 4 quarters average of 66.7

Efficiency

How efficient is BioAge Labs business performance
The ROIC has soared by 73% YoY and by 32% from the previous quarter
BIOA's return on sales has surged by 55% year-on-year but it is down by 4.9% since the previous quarter
BIOA's ROA is down by 17% year-on-year
BIOA's ROE is down by 14% year-on-year

Dividends

What is BIOA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIOA.

Financial health

How did BioAge Labs financials performed over time
BIOA's current ratio is down by 31% since the previous quarter but it is up by 30% year-on-year
BIOA's quick ratio is down by 31% since the previous quarter but it is up by 27% year-on-year
BIOA's debt is 99% smaller than its equity
BIOA's debt has dropped by 68% year-on-year and by 30% since the previous quarter
The debt to equity has dropped by 67% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.